TheraRadar
Data updated: May 30, 2026

DIFFERIN EPIDUO ACNE GEL (ADAPALENE AND BENZOYL PEROXIDE) (adapalene, benzoyl peroxide)

Approved 2026-05-22
1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Prescription
First Approved
2026-05-22
Routes
N/A
Dosage Forms
GEL

DIFFERIN EPIDUO ACNE GEL (ADAPALENE AND BENZOYL PEROXIDE) Approval History

Original
New Indication
New Form
Label Update
4 FDA actions from 2026 to 2026
May 2026 ORIGINAL
Update · Type 8 - Partial Rx to OTC Switch

What DIFFERIN EPIDUO ACNE GEL (ADAPALENE AND BENZOYL PEROXIDE) Treats

1 FDA approvals

Originally approved for its first indication in 2026 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DIFFERIN EPIDUO ACNE GEL (ADAPALENE AND BENZOYL PEROXIDE) FDA Label Details

Track DIFFERIN EPIDUO ACNE GEL (ADAPALENE AND BENZOYL PEROXIDE) with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.